2001 M Street NW
10th Floor
Washington, DC 20036

+1 202 847 4030

Local Litigation Star

National Practice Area Star


District of Columbia

Practice area:

Product liability
White collar crime

Brian is a go-to first-chair trial lawyer who has tried nearly 30 cases. As a founding partner of Wilkinson Stekloff, Brian has served as lead or co-lead trial counsel in high-stakes trials, including major products liability bellwethers. Among his many trial victories was the first jury verdict for Bayer in the Xarelto mass tort proceedings in the Philadelphia Court of Common Pleas. In recognition of that success, Chambers recently named Brian an “up and coming” trial lawyer in products liability and mass torts, describing him as “a tremendous lawyer” who is “instrumental in getting favorable results.” 

Before founding Wilkinson Stekloff, Brian practiced at Covington and Burling and Paul, Weiss, Rifkind, Wharton & Garrison in Washington DC, where he tried multiple cases to verdict and represented companies and individuals in government investigations and prosecutions. Earlier in his career, Brian spent four years as an Assistant Federal Public Defender for the Southern District of Florida, where he obtained full acquittals in nearly one-third of his jury trials at a rate of double the national average. 

After his Philadelphia win, Brian was selected to serve as lead trial counsel in Hardeman v. Monsanto, the first federal-court trial over allegations that Roundup causes Non-Hodgkin’s Lymphoma. Brian led the pretrial strategy in front of Judge Vince Chhabria, including on a successful motion to “reverse bifurcate” the trial with a first phase focused on causation. The jury returned a verdict for the plaintiff; Brian then led post-trial briefing, which cut the damages award by over two-thirds. The case is currently on appeal to the Ninth Circuit Court of Appeals. 

In addition to continuing to serve as lead counsel in the federal MDL proceedings over Roundup, Brian is also serving as co-lead trial counsel for Glenmark Pharmaceuticals in criminal antitrust proceedings in the Eastern District of Pennsylvania. 


Updated Sep 2021